Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.

Saved in:
Bibliographic Details
Title: Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
Authors: Stelljes M; Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany., Raffel S; Department of Medicine, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany., Alakel N; Medizinische Klinik und Poliklinik I, Universitätsklinikum, Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany., Wäsch R; Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Kondakci M; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany., Scholl S; Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany., Rank A; Department of Hematology and Oncology, University Medical Center Augsburg, Augsburg, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Spriewald B; Department of Internal Medicine V, Hematology and Oncology, University of Erlangen-Nuremberg, Erlangen, Germany., Hanoun M; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany., Martin S; Department of Hematology and Oncology, Robert-Bosch-Hospital, Stuttgart, Germany., Schwab K; Department of Medicine III, Hematology, Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany., Serve H; Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Frankfurt, Germany., Reiser L; Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Frankfurt, Germany., Knaden J; Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Frankfurt, Germany., Pfeifer H; Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Frankfurt, Germany., Marx J; Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany., Sauer T; Department of Medicine, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany., Berdel WE; Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany., Lenz G; Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany., Brüggemann M; Department of Medicine II, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Gökbuget N; Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Frankfurt, Germany., Wethmar K; Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jan 20; Vol. 42 (3), pp. 273-282. Date of Electronic Publication: 2023 Oct 26.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.23.00546